After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

ITOS Company Profile iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second ...

Notable biotech financings in the last week include a $120m direct offering for iTeos, and private rounds for Lycia, Attovia, Ajax, and CinDome.

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth ...

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $5.00. The company’s shares closed yesterday at $1.49. El ...

Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company’s ...